Products - Prostate cancer | Topic

Showing 13 products

Date | Sort by Title

Status: In developmentRemove ‘Status: In development’ filter

SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer
Status:
In development
Programme:
Medical technologies guidance
Expected publication date:
16 March 2020
Enzalutamide with androgen deprivation therapy for untreated metastatic hormone-sensitive prostate cancer [ID1605]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
22 May 2020
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Prostate cancer (hormone refractory) - atrasentan [ID390]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Prostate cancer (prevention) - dutasteride [ID75]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Enzalutamide for the treatment of hormone refractory prostate cancer TA316
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer (ID1174)
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apalutamide for treating metastatic hormone-sensitive prostate cancer ID1534
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Darolutamide for treating non-metastatic hormone-relapsed prostate cancer ID1443
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Prostate cancer Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 13 products

SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer

Enzalutamide with androgen deprivation therapy for untreated metastatic hormone-sensitive prostate cancer [ID1605]

Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

Prostate cancer (hormone refractory) - atrasentan [ID390]

Prostate cancer (prevention) - dutasteride [ID75]

Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

Enzalutamide for the treatment of hormone refractory prostate cancer TA316

Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer (ID1174)

Apalutamide for treating metastatic hormone-sensitive prostate cancer ID1534

Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

Darolutamide for treating non-metastatic hormone-relapsed prostate cancer ID1443

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 13 products

Status
1 selected